Scholarlink

Background <p>Camrelizumab combined with radiotherapy may offer an effective neoadjuvant option for locally advanced esophageal squamous cell carcinoma while reducing chemotherapy-related toxicity. We assessed the efficacy and safety of this chemotherapy-sparing regimen.</p> Methods <p>In this single-arm phase II trial, adults with resectable thoracic esophageal squamous cell carcinoma received camrelizumab 200&#xa0;mg intravenously every 3&#xa0;weeks for two cycles, concurrently with radiotherapy to 41.4&#xa0;Gy in 23 fractions, followed by esophagectomy 4–8&#xa0;weeks later. The primary endpoint was major pathologic response (≤ 10% residual viable tumor) among patients undergoing resection. Secondary endpoints were R0 resection rate, pathologic complete response, treatment-related adverse events, postoperative complications, and survival outcomes. Trial registration: ClinicalTrials.gov NCT05176002.</p> Results <p>Twenty-five patients were enrolled; three did not undergo surgery (one radiographic complete response with refusal of surgery, one disease progression, and one withdrawal). Twenty-two patients (88%) had esophagectomy, all with R0 resection. Major pathologic response occurred in 12 of 22 patients (54.5%), including pathologic complete response in 8 (36.4%). No grade 3 or higher treatment-related adverse events were observed; the most frequent toxicities were low-grade radiation esophagitis, leukopenia, dermatitis, and hypothyroidism. Postoperative complications were low grade. At a median follow-up of 36&#xa0;months, five recurrences were recorded, with survival comparable to historical standard neoadjuvant cohorts.</p> Conclusions <p>Neoadjuvant camrelizumab plus radiotherapy showed low toxicity, pathologic tumor regression, and favorable postoperative outcomes in resectable esophageal squamous cell carcinoma. This chemotherapy-sparing approach may be an alternative for patients who are unsuitable for or intolerant of standard chemotherapy-based neoadjuvant regimens.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neoadjuvant camrelizumab combined with radiotherapy as a chemotherapy-sparing approach for resectable locally advanced esophageal squamous cell carcinoma: a phase II clinical trial (ESOCORT-NIRT)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Maohui Chen,
  • Yizhou Huang,
  • Shuliang Zhang,
  • Cheng Chen,
  • Taidui Zeng,
  • Hongmu Li,
  • Zhenyuan Yang,
  • Chuanquan Lin,
  • Wei Li,
  • Benhua Xu,
  • Chun Chen,
  • Bin Zheng

摘要

Background

Camrelizumab combined with radiotherapy may offer an effective neoadjuvant option for locally advanced esophageal squamous cell carcinoma while reducing chemotherapy-related toxicity. We assessed the efficacy and safety of this chemotherapy-sparing regimen.

Methods

In this single-arm phase II trial, adults with resectable thoracic esophageal squamous cell carcinoma received camrelizumab 200 mg intravenously every 3 weeks for two cycles, concurrently with radiotherapy to 41.4 Gy in 23 fractions, followed by esophagectomy 4–8 weeks later. The primary endpoint was major pathologic response (≤ 10% residual viable tumor) among patients undergoing resection. Secondary endpoints were R0 resection rate, pathologic complete response, treatment-related adverse events, postoperative complications, and survival outcomes. Trial registration: ClinicalTrials.gov NCT05176002.

Results

Twenty-five patients were enrolled; three did not undergo surgery (one radiographic complete response with refusal of surgery, one disease progression, and one withdrawal). Twenty-two patients (88%) had esophagectomy, all with R0 resection. Major pathologic response occurred in 12 of 22 patients (54.5%), including pathologic complete response in 8 (36.4%). No grade 3 or higher treatment-related adverse events were observed; the most frequent toxicities were low-grade radiation esophagitis, leukopenia, dermatitis, and hypothyroidism. Postoperative complications were low grade. At a median follow-up of 36 months, five recurrences were recorded, with survival comparable to historical standard neoadjuvant cohorts.

Conclusions

Neoadjuvant camrelizumab plus radiotherapy showed low toxicity, pathologic tumor regression, and favorable postoperative outcomes in resectable esophageal squamous cell carcinoma. This chemotherapy-sparing approach may be an alternative for patients who are unsuitable for or intolerant of standard chemotherapy-based neoadjuvant regimens.